By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Swedish Orphan Biovitrum 

SE-112

  76 Stockholm    Sweden
Phone: 46-8-697-20-00 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Swedish Orphan Biovitrum's Orfadin Oral Suspension Granted European Patent 1/19/2016 9:11:40 AM
Chief Medical Officer Birgitte Volck To Leave Swedish Orphan Biovitrum 1/14/2016 11:24:55 AM
Swedish Orphan Biovitrum Announces Commercial Launch Of Elocta In First Countries In Europe 1/11/2016 9:36:50 AM
Swedish Orphan Biovitrum Gains Commercial Rights For Relistor, Deflux And Solesta From Pharmaswiss 1/7/2016 10:43:34 AM
Swedish Orphan Biovitrum Receives Orphan Drug Designation For Alprolix In Switzerland 12/22/2015 9:09:59 AM
Swedish Orphan Biovitrum And Biogen (BIIB)’s ELOCTA (rFVIIIFc) Approved In Europe For The Treatment Of Haemophilia A 11/24/2015 10:50:56 AM
Swedish Orphan Biovitrum Release: European Medicines Agency Approves Xiapex For Concurrent Treatment Of Palpable Cords 11/17/2015 10:18:35 AM
Swedish Orphan Biovitrum Publishes Its Report For The Third Quarter 2015 10/29/2015 10:04:01 AM
Swedish Orphan Biovitrum Release: Xiapex Approved For The Treatment Of Peyronie's Disease In Switzerland 10/16/2015 11:08:00 AM
Biogen (BIIB) And Swedish Orphan Biovitrum Receive Positive Opinion From CHMP For Elocta (Rfviiifc) For The Treatment Of Hemophilia A 9/25/2015 9:07:38 AM
123456789
//-->